Successful completion of the multi-center trial with autologous cell therapy APN401 marks a key step forward toward clinical use. APN401 shows a favorable safety profile and promising efficacy signals in...

Vienna, Austria, 16 December 2024: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, will be participating in JP Morgan week activities in San Francisco, January...

Funding secures ongoing pipeline progress and achievement of preclinical and clinical milestones Oral small molecule INV501: collaboration with Dana-Farber Cancer Institute (DFCI) making good progress; target validation and details of…

This is particularly fitting as today is Glioblastoma Awareness Day, to recognize the impact of this most aggressive form of brain cancer and highlight the need to advance research, raise...

• Preclinical study will be conducted by Dr. David Reardon’s research group • Immune-activating small molecule INV501 will be tested as treatment for aggressive brain cancer Vienna, Austria and Boston,…

Multi-center trial of novel autologous cell therapy APN401 leveraging two GMP-compliant manufacturing sites has received regulatory approval and patient recruitment has started; invIOs awarded up to 45% funding of trial…

INV501, a potentially first-in-class compound, induces strong anti-tumor immune responses in preclinical models in different solid tumor indications Treatment with INV501 significantly inhibits tumor growth, extends survival and increases cure...

APN401 induced prolonged stable disease in two heavily pre-treated patients, using invIOs’s proprietary rapid cell-processing platform technology to manufacture Cbl-b silenced PBMCs and deliver treatment in under 24 hours Data...